Phase i study of the histone deacetylase inhibitor entinostat in combination with 13-cis retinoic acid in patients with solid tumours

British Journal of Cancer

Volumn 106, Issue 1, 2012, Pages 77-84

  Pili, R ^a   Salumbides, B ^a   Zhao, M ^a   Altiok, S ^a   Qian, D ^a   Zwiebel, J ^b   Carducci, M A ^a   Rudek, M A ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

histone deacetylase inhibitor; retinoic acid receptor; solid tumours

Indexed keywords

ENTINOSTAT; ISOTRETINOIN; MITOGEN ACTIVATED PROTEIN KINASE;

ADULT; AGED; ANOREXIA; ARTICLE; BREAST CANCER; CANCER PATIENT; CLINICAL ARTICLE; COLON; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG EFFECT; DRUG EXPOSURE; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DRY SKIN; FATIGUE; FEMALE; HALF LIFE TIME; HEADACHE; HUMAN; HYPERGLYCEMIA; HYPOALBUMINEMIA; HYPOCALCEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; KIDNEY CANCER; LEIOMYOSARCOMA; LEUKOCYTE; LIQUID CHROMATOGRAPHY; LUNG CANCER; MALE; MASS SPECTROMETRY; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MELANOMA; MENINGIOMA; MESOTHELIOMA; NAUSEA; NEUTROPHIL; PANCREAS CANCER; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; SIDE EFFECT; SOLID TUMOR; TASTE DISORDER; THROMBOCYTE; TRANSITIONAL CELL CARCINOMA; VOMITING; WESTERN BLOTTING; XEROSTOMIA;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZAMIDES; BLOTTING, WESTERN; CHROMATOGRAPHY, LIQUID; FEMALE; HISTONE DEACETYLASE INHIBITORS; HUMANS; ISOTRETINOIN; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; PYRIDINES; TANDEM MASS SPECTROMETRY; TREATMENT OUTCOME;

EID: 84855340600     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2011.527     Document Type: Article

References (35)

1. Accutane (Isotretinoin) Capsules Package Insert. Roche Laboratories, Inc.: Nutyley, NJ (2000)
2. Agadir A, Cornic M, Lefebvre P, Gourmel B, Jerome M, Degos L, Fenaux P, Chomienne C (1995) All-trans retinoic acid pharmacokinetics and bioavailability in acute promyelocytic leukemia: intracellular concentrations and biologic response relationship. J Clin Oncol 13: 2517-2523
3. Altucci L, Gronemeyer H (2001) The promise of retinoids to fight against cancer. Nat Rev Cancer 1: 181-193 (Pubitemid 33741893)
4. Blumenschein Jr GR, Kies MS, Papadimitrakopoulou VA, Lu C, Kumar AJ, Ricker JL, Chiao JH, Chen C, Frankel SR (2008) Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer. Invest New Drugs 26: 81-87
5. Bovenzi V, Momparler RL (2001) Antineoplastic action of 5-aza-20-deoxycytidine and histone deacetylase inhibitor and their effect on the expression of retinoic acid receptor-b and estrogen receptor-a genes in breast carcinoma cells. Cancer Chemother Pharmacol 48: 71-76 (Pubitemid 32662439)
6. Byrd JC, Marcucci G, Parthun MR, Xiao JJ, Klisovic RB, Moran M, Lin TS, Liu S, Sklenar AR, Davis ME, Lucas DM, Fischer B, Shank R, Tejaswi SL, Binkley P, Wright J, Chan KK, Grever MR (2005) A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocy-tic leukemia and acute myeloid leukemia. Blood 105: 959-967 (Pubitemid 40170861)
7. Chen JY, Clifford J, Zusi C, Starrett J, Tortolani D, Ostrowski J, Reczek PR, Chambon P, Gronemeyer H (1996) Two distinct actions of retinoid-receptor ligands. Nature 382: 819-822 (Pubitemid 26299567)
8. Conley BA, Egorin MJ, Sridhara R, Finley R, Hemady R, Wu S, Tait NS, Van Echo DA (1997) Phase I clinical trial of all-trans-retinoic acid with correlation of its pharmacokinetics and pharmacodynamics. Cancer Chemother Pharmacol 39: 291-299 (Pubitemid 27047473)
9. David KA, Mongan NP, Smith C, Gudas LJ, Nanus DM (2010) Phase I trial of ATRA-I V and depakote in patients with advanced solid tumors malignancies. Cancer Biol Ther 9: 678-684
10. De Lera AR, Bourguet W, Altucci L, Gronemeyer H (2007) Design of selective nuclear receptor modulators: RAR and RXR as a case study. Nat Rev Drug Discov 6: 811-820 (Pubitemid 47504872)
11. Ellis L, Atadja PW, Johnstone RW (2009) Epigenetics in cancer: targeting chromatin modifications. Mol Cancer Ther 8: 1409-1420
12. Ellis L, Pan Y, Smyth GK, George DJ, McCormack C, Williams-Truax R, Mita M, Beck J, Burris H, Ryan G, Atadja P, Butterfoss D, Dugan M, Culver K, Johnstone RW, Prince HM (2008) Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma. Clin Cancer Res 14: 4500-4510
13. Garcia-Manero G, Assouline S, Cortes J, Estrov Z, Kantarjian H, Yang H, Newsome WM, Miller Jr WH, Rousseau C, Kalita A, Bonfils C, Dubay M, Patterson TA, Li Z, Besterman JM, Reid G, Laille E, Martell RE, Minden M (2008) Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia. Blood 112: 981-989
14. Gibaldi MPD (1982) Noncompartmental analysis based on statistical moment theory. Marcel Decker (ed). In Pharmacokinetics, pp 409-417. Marcel Dekker: New York
15. Gilbert J, Baker SD, Bowling MK, Grochow L, Figg WD, Zabelina Y, Donehower RC, Carducci MA (2001) A phase I dose escalation and bioavailability study of oral sodium phenylbutyrate in patients with refractory solid tumor malignancies. Clin Cancer Res 7: 2292-2300 (Pubitemid 32751627)
16. Gore L, Rothenberg ML, O'Bryant CL, Schultz MK, Sandler AB, Coffin D, McCoy C, Schott A, Scholz C, Eckhardt SG (2008) A phase I and pharmacokinetic study of the oral histone deacetylase inhibitor, MS-275, in patients with refractory solid tumors and lymphomas. Clin Cancer Res 14: 4517-4525
17. Kato Y, Salumbides BC, Wang XF, Qian DZ, Williams S, Wei Y, Sanni TB, Atadja P, Pili R (2007) Antitumor effect of combination of retinoic acid with the histone deacetylase inhibitor LAQ824 in malignant melanoma. Mol Cancer Ther 6: 70-81 (Pubitemid 46206669)
18. Kizaki M, Ueno H, Yamazoe Y, Shimada M, Takayama N, Muto A, Matsushita H, Nakajima H, Morikawa M, Koeffler HP, Ikeda Y (1996) Mechanisms of retinoid resistance in leukemic cells: possible role of cytochrome P450 and P-glycoprotein. Blood 87: 725-733 (Pubitemid 26030329)
19. Lin B, Chen G, Xiao D, Kolluri SK, Cao X, Su H, Zhang XK (2000) Orphan receptor COUP-TF is required for induction of retinoic acid receptor-b, growth inhibition, and apoptosis by retinoic acid in cancer cells. Mol Cell Biol 20: 957-970 (Pubitemid 30044233)
20. Marks P, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK (2001) Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer 1: 194-202 (Pubitemid 33741894)
21. Muindi JR, Frankel SR, Huselton C, DeGrazia F, Garland WA, Young CW, Warrell Jr RP (1992) Clinical pharmacology of oral all-trans retinoic acid in patients with acute promyelocytic leukemia. Cancer Res 52: 2138-2142
22. Olsen EA, Kim YH, Kuzel TM, Pacheco TR, Foss FM, Parker S, Frankel SR, Chen C, Ricker JL, Arduino JM, Duvic M (2007) Phase IIb multi-center trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneousT-cell lymphoma. J Clin Oncol 25: 3109-3115 (Pubitemid 47218059)
23. Piekarz RL, Frye R, Turner M, Wright JJ, Allen SL, Kirschbaum MH, Zain J, Prince HM, Leonard JP, Geskin LJ, Reeder C, Joske D, Figg WD, Gardner ER, Steinberg SM, Jaffe ES, Stetler-Stevenson M, Lade S, Fojo AT, Bates SE (2009) Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J Clin Oncol 27: 5410-5417
24. Pili R, Kruszewski MP, Brandt H, Lantz J, Carducci MA (2001) Combination of phenylbutyrate and 13-cis retinoic acid inhibits prostate tumor growth and angiogenesis. Cancer Res 61: 1477-1485 (Pubitemid 34292576)
25. Rathkopf D, Wong BY, Ross RW, Anand A, Tanaka E, Woo MM, Hu J, Dzik-Jurasz A, Yang W, Scher HI (2010) A phase I study of oral panobinostat alone and in combination with docetaxel in patients with castration-resistant prostate cancer. Cancer Chemother Pharmacol 66: 181-189
26. Saito A, Yamashita T, Mariko Y, Nosaka Y, Tsuchiya K, Ando T, Suzuki T, Tsuruo T, Nakanishi O (1999) A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors. Proc Natl Acad Sci USA 96: 4592-4597 (Pubitemid 29190381)
27. Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, Eisenberger MA, Higano C, Bubley GJ, Dreicer R, Petrylak D, Kantoff P, Basch E, Kelly WK, Figg WD, Small EJ, Beer TM, Wilding G, Martin A, Hussain M (2008) Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 26: 1148-1159
28. Sirchia SM, Ferguson AT, Sironi E, Subramanian S, Orland R, Sukumar S, Sacchi N (2000) Evidence of epigenetic changes affecting the chromatin state of the retinoic acid receptorb2 promoter in breast cancer cells. Oncogene 19: 1556-1563 (Pubitemid 30175677)
29. Tavares TS, Nanus DM, Yang X, Gudas LJ (2008) Gene microarray analysis of human renal cell carcinoma: the effects of HDAC inhibition and retinoid treatment. Cancer Biol Ther 7: 1607-1618
30. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, Van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216
31. Thurn KT, Thomas S, Moore A, Munster PN (2011) Rational therapeutic combinations with histone deacetylase inhibitors for the treatment of cancer. Future Oncol 2: 263-283
32. Touma SE, Goldberg JS, Moench P, Guo X, Tickoo SK, Gudas LJ, Nanus DM (2005) Retinoic acid and the histone deacetylase inhibitor trichostatin a inhibit the proliferation of human renal cell carcinoma in a xenograft tumor model. Clin Cancer Res 11: 3558-3566 (Pubitemid 40627912)
33. Wang XF, Qian DZ, Ren M, Kato Y, Wei Y, Zhang L, Fansler Z, Clark D, Nakanishi O, Pili R (2005) Epigenetic modulation of retinoic acid receptor beta2 by the histone deacetylase inhibitor MS-275 in human renal cell carcinoma. Clin Cancer Res 11: 3535-3542 (Pubitemid 40627909)
34. Widschwendter M, Berger J, Hermann M, Muller HM, Amberger A, Zeschnigk M, Widschwendter A, Abendstein B, Zeimet AG, Daxenbichler G, Marth C (2000) Methylation and silencing of the retinoic acid receptor-beta2 gene in breast cancer. J Natl Cancer Inst 92: 826-832 (Pubitemid 30368039)
35. Zhao M, Rudek MA, Mnasakanyan A, Hartke C, Pili R, Baker SD (2007) A liquid chromatography/tandem mass spectrometry assay to quantitate MS-275 in human plasma. J Pharm Biomed Anal 43: 784-787 (Pubitemid 44960582)